Background Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated
inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, …

Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective, …

Background Functional impairment of interferon, a natural antiviral component of the
immune system, is associated with the pathogenesis and severity of COVID-19. We aimed to …

The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost to …

Background Baricitinib and dexamethasone have randomised trials supporting their use for
the treatment of patients with COVID-19. We assessed the combination of baricitinib plus …

Vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection wanes over time, requiring updated boosters. In a phase 2, open-label, …

Background: While Coronavirus disease 2019 (Covid-19) vaccines are highly effective,
breakthrough infections are occurring. Booster vaccinations have recently received emergency …

Background Protection from SARS-CoV-2 vaccines wanes over time and is compounded by
emerging variants including Omicron subvariants. This study evaluated safety and …

Clostridium difficile causes antibiotic-associated diarrhea and is a major public health concern.
Current therapies disrupt the protective intestinal flora, do not reliably prevent recurrent …

Background Bacteriophages (phages) are a promising anti-infective option for human disease.
Major gaps remain in understanding their potential utility. Methods This is a randomized, …